3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
16
Phase 1
8
Phase 3
4
Phase 1/2
4
Phase 2/3
2
Phase 4
1
Status
Recruiting
2
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Other hematologic neoplasm
2
Thoracic
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
5
Stomach Neoplasms
4
HER2-positive Breast Cancer
3
Neoplasms
2
Hematologic Neoplasms
2
Urinary Bladder Neoplasms
1
Skin Neoplasms
1
Salivary Gland Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Lymphoproliferative Disorders
1
Lung Neoplasms
1
HER2-positive Gastric Cancer
1
Gallbladder Neoplasms
1
Colorectal Neoplasms
1
Adenocarcinoma Of Esophagus
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
Trastuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled
NCT05722886
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
825 enrolled